ParaPharm Development Ltd. (PPDV) is privately-owned and works closely with other similar companies, including:
- European Specialty Pharma – Nordic Pharma Group
- Life Science Investment Fund
- Transdermal Limited
- Altacor Limited
Background
ParaPharm Development Ltd. (PPDV) was incorporated in January 2016 as a spin off from Nordic Pharma Ltd. PPDV started trading in July 2016.
Once a product has been developed and gained the necessary regulatory approvals, PPDV can access a commercial pathway through companies covering the EU and potentially across the globe. This enables greater commercial viability for niche products.
PPDV actively collaborates with expert regulatory partners around the world to allow preparation of formulation and clinical dossiers.
To complement this, an experienced commercial team with a strong track record focuses on market assessments, launch plans as well as undertaking due diligence to gain a greater understanding of the payer and clinical environment.